ClinicalTrials.gg
CompletedNCT06850922THAMESUpdated Jun 23, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

A Phase 1/2 interventional study of RO7446603 and Aflibercept in Diabetic Macular Edema, sponsored by Genentech, Inc.. Completed at 77 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jun 2022, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
11th of 25
388 · median 377
Started
2022
with 3 others
Phase 1/2
Only one
of the 28
Registered
27th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2022, is the only one in phase 1/2, and was the 27th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of diabetes mellitus (DM) (Type 1 or Type 2) with (HbA1c) \< 12%
  • Macular thickening secondary to DME involving the center of the fovea > 325 microns
  • Decreased VA attributable primarily to DME between 25 and 73 ETDRS letters

Exclusion criteria

Exclusion Criteria:

  • Currently untreated DM or previously untreated participants who initiated oral anti-diabetic medication or insulin within 90 days prior to Day 1
  • Uncontrolled blood pressure (BP)
  • Pregnancy or breastfeeding, or intention to become pregnant during the study
  • For Parts 1-4: IVT anti-VEGF treatment within 90 days prior to Day 1; For Part 5: IVT anti-VEGF treatment within 120 days prior to Day 1 or IVT anti-VEGF treatment prior to Day 1 for treatment naïve participants
  • Treatment with SUSVIMOTM (ranibizumab injection) prior to Day 1
  • Any IVT or periocular (sub-tenons) treatment within 6 months prior to Day 1
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision
  • Proliferative diabetic retinopathy (PDR) in the study eye
  • Active or history of uveitis, vitritis (grade trace or above), and/or scleritis in either eye Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Part 1: Single Ascending Dose (SAD) Stage

    Participants received a single dose of RO7446603 at five different dose levels as IVT injection on Day 1.

    Drug: RO7446603

  • Experimental
    Part 2: Multiple Dose (MD) Monotherapy Stage

    Participants received four different dose levels of RO7446603 (two doses at each planned dose level) as IVT injection, every 8 weeks (Q8W).

    Drug: RO7446603

  • Experimental
    Part 3: MD Co-administration With Aflibercept Stage

    Participants received two different dose levels (two doses at each planned dose level) of RO7446603 as IVT injection, Q8W along with four doses of aflibercept IVT injections, every 4 weeks (Q4W).

    Drug: RO7446603 · Drug: Aflibercept

  • Experimental
    Part 4: MD Co-administration With Faricimab Stage

    Participants received a single dose of faricimab followed by a 4-week enrichment screening period. Eligible participants received two different dose levels (two doses at each planned dose level) of RO7446603 as IVT injection, Q8W, along with three doses of faricimab (co-administered with RO7446603 or alone) as IVT injection, Q4W.

    Drug: RO7446603 · Drug: Faricimab

  • Experimental
    Part 5: MD Co-mixed With Faricimab Stage

    Participants will receive two different dose levels of RO7446603 (co-mixed with faricimab or faricimab alone) as IVT injection, Q4W for the first six doses followed by Q8W for four doses.

    Drug: RO7446603 · Drug: Faricimab

Interventions

  • DrugRO7446603

    Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.

  • Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.

  • Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.

    Also known as: Vabysmo

06

What researchers measure

Primary outcomes

  1. Parts 1-5: Percentage of Participants With Adverse Events (AEs)

    Time frame: From study start through end of study (Up to approximately 58 months)

  2. Parts 1-5: Percentage of Participants With Ocular AEs

    Time frame: From study start through end of study (Up to approximately 58 months)

  3. Part 1: Change in Best Corrected Visual Acuity (BCVA) Over Time

    BCVA will be measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 16

  4. Parts 2-4: Change in BCVA Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 28

  5. Part 5: Change From Baseline in BCVA Averaged Over Weeks 52 and 56

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 56

Secondary outcomes

  1. Part 5: Proportion of Participants Gaining ≥ 15 Letters in BCVA From Baseline Averaged Over Weeks 52 and 56

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 56

  2. Part 5: Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 56

  3. Part 5: Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 56

  4. Part 5: Change From Baseline in BCVA Score Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA.

    Time frame: From Baseline up to Week 56

  5. Parts 1-4: Serum Concentration of RO7446603 Total Fab

    Time frame: Part 1: From Baseline up to Week 16; Parts 2-4: From Baseline up to Week 28

  6. Parts 1-5: Aqueous Humor Concentration of RO7446603 Measured as Total Fab

    Time frame: From study start through end of study (Up to approximately 58 months)

  7. Parts 1-5: Number of Participants With Serum Treatment-emergent Anti-drug Antibody (ADA) Formation to RO7446603

    Time frame: From study start through end of study (Up to approximately 58 months)

07

Study locations

77 sites
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85020-5917, United States
  • Associated Retinal Consultants PC
    Phoenix, Arizona 85020, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85053, United States
  • Retina Partners of Northwest Arkansas, PLLC
    Springdale, Arkansas 72764, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Retinal Consultants Medical Group
    Modesto, California 95356-9412, United States
  • Northern California Retina-Vitreous Associates
    Mountain View, California 94040, United States
  • Retinal Consultants Medical Group
    Sacramento, California 95825, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Macula Retina Vitreous Research Institute
    Torrance, California 90503-3270, United States
  • Bay Area Retina Associates;Study Department
    Walnut Creek, California 94598, United States
  • University of Colorado - Eye Center - PPDS
    Aurora, Colorado 80045-2517, United States
  • Retina Consultants of Southern Colorado PC
    Colorado Springs, Colorado 80909, United States
  • Retina Specialists of Colorado
    Denver, Colorado 80222, United States
  • Advanced Vision Research Institute
    Longmont, Colorado 80503-6499, United States
  • Retina Group of New England
    Waterford, Connecticut 06385-1215, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Retina Institute
    Jacksonville, Florida 32216-6347, United States
  • Retina Associates of Florida;Retina Associates of Florida
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909-6440, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    ‘Aiea, Hawaii 96701, United States
  • Illinois Eye and Ear Infirmary
    Chicago, Illinois 60612, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Raj K. Maturi, MD PC
    Indianapolis, Indiana 46290, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Chesapeake Retina Centers - Waldorf
    Waldorf, Maryland 20602, United States
  • Associated Retinal Consultants - Royal Oak
    Royal Oak, Michigan 48073, United States
  • Retina Consultants Minnesota
    Saint Louis Park, Minnesota 55416, United States
  • Long Island Vitreoretinal Consultants;Opthalmology
    Hauppauge, New York 11788, United States
  • Retina Vitreous Surgeons of CNY PC
    Liverpool, New York 13088, United States
  • Opthalmic Consultants of LI
    Lynbrook, New York 11563, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • North Carolina Retina Associates
    Cary, North Carolina 27511, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Graystone Eye-Hickory
    Hickory, North Carolina 28602, United States
  • North Carolina (NC) Retina Associates - Wake Forest Office
    Wake Forest, North Carolina 27587-3803, United States
  • Piedmont Retina Specialists
    Winston-Salem, North Carolina 27103-6970, United States
  • Cincinnati Eye Institute
    Blue Ash, Ohio 45242-5537, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44016, United States
  • Ohio State Eye and Ear Institute
    Columbus, Ohio 43212, United States
  • Tulsa Retina Consultants
    Tulsa, Oklahoma 74114, United States
  • Cascade Medical Research Institute LLC
    Springfield, Oregon 97477, United States
  • Erie Retina Research
    Erie, Pennsylvania 16505, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107-5109, United States
  • Sewickely Eye Group
    Sewickley, Pennsylvania 15143, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169-2429, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Arlington, Texas 76012, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina & Vitreous of Texas
    Bellaire, Texas 77401, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Valley Retina Institute P.A.
    McAllen, Texas 78550-9207, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas - San Antonio
    San Antonio, Texas 78240, United States
  • Brown Retina Institute
    San Antonio, Texas 78251-4551, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah, PLLC;Clinical Research
    Salt Lake City, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502-4271, United States
  • Wagner Kapoor Institute
    Norfolk, Virginia 23502, United States
  • Virginia Eye Institute - Richmond - 7301 Forest Ave
    Richmond, Virginia 23230, United States
  • Retina Institute of Virginia
    Richmond, Virginia 23235-1962, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • Shanghai General Hospital - North Campus
    Shanghai, Shanghai Municipality 200080, China
  • Tianjin Medical University Eye Hospital
    Tianjin, Tianjin Municipality 300384, China
  • Eye Hospital,WMU(Zhejiang Eye Hospital)
    Wenzhou, Zhejiang 325027, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Emanuelli Research and Development Center LLC
    Arecibo, 00612, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2026, 46 months.

Of 16 phase 1/2 interventional studies under Macular Edema, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 68. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Feb 28, 2025
StartActual
Jun 22, 2022
Primary completionActual
May 19, 2026
CompletionActual
Jun 19, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06850922
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Jun 22, 2022
Primary completion
May 19, 2026
Completion
Jun 19, 2026
Last update
Jun 23, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion